New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...tilus Biotech Commences Phase I Study for Belerofon(R) II-58 Migenix Announces Phase II Proof-of-Concept Study Results of Celgosivir II-59 pharmasset Begins Multiple Dose-Escalating Study of R7128 II-59 Transgene Commences Phase I Trial of TG4040 II-59 Debiopharm Releases Phase Ib Results of...

Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development

...s part of a future treatment regimen. About pharmasset pharmasset is a clinical-stage pharmaceutical company committ...) 613-4181 Forward-Looking Statements pharmasset "Safe Harbor" Statement under the Private Securiti...

Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients

...all of the most common HCV genotypes. About pharmasset pharmasset is a clinical-stage pharmaceutical company committ...) 613-4181 Forward-Looking Statements pharmasset "Safe Harbor" Statement under the Private Securiti...

Pharmasset to Present at Deutsche Bank Healthcare Conference

...stor.pharmasset.com/events.cfm . About pharmasset pharmasset is a clinical-stage pharmaceutical company committ...) 613-4181 Forward-Looking Statements pharmasset "Safe Harbor" Statement under the Private Securiti...

Pharmasset to Present at Two Upcoming Investor Conferences

...tor.pharmasset.com/events.cfm . About pharmasset pharmasset is a clinical-stage pharmaceutical company committ...(HCV) and human immunodeficiency virus (HIV). pharmasset is currently developing four product candidates. ...

Pharmasset to Present at Two Upcoming Investor Conferences

...estor.pharmasset.com/events.cfm . About pharmasset pharmasset is a clinical-stage pharmaceutical company committ...(HCV) and human immunodeficiency virus (HIV). pharmasset is currently developing four product candidates. ...

InterMune Reports Results from Triple Combination Study of ITMN-191

...es for 30 days following the completion of study treatment. INFORM-1 Progress (All-oral STAT-C study) In November 2008, Roche, InterMune and pharmasset initiated the first all-oral combination study of direct anti-virals in the absence of interferon or ribavirin, known as the INFORM-1 study. That stu...

Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference

...//investor.pharmasset.com/events.cfm . About pharmasset pharmasset is a clinical-stage pharmaceutical company committ...(HCV) and human immunodeficiency virus (HIV). pharmasset is currently developing three product candidates. ...

Pharmasset to Webcast an Investor Event from the AASLD Meeting

...esented discussing clevudine. About Pharmasset pharmasset is a clinical-stage pharmaceutical company committ...us (HCV) and human immunodeficiency virus (HIV). pharmasset is currently developing three product candidates. ...e: +1 (609) 613-4181 Forward-Looking Statements pharmasset "Safe Harbor" Statement under the Private Securiti...

Pharmasset Reports Financial Results for Quarter Ended March 31, 2008

...or the second fiscal quarter ended March 31, 2008. pharmasset reported a net loss attributable to common stockho...urred during October 2007. As of March 31, 2008, pharmasset had approximately $63.0 million of cash and cash e...rst-in-human clinical trials. About Pharmasset pharmasset is a clinical-stage pharmaceutical company committ...

Pharmasset in Medical Technology

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

Start of trial triggers $10 million milestone payment to Pharmasset PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) and Roche (Roche SWX: RO, ROG; Pink Sheets: RHHBY) today announced that the first patient has been dosed in a Phase IIb study of R7128, th...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ), Roche (SWX: ROG) and InterMune, Inc. (Nasdaq: ITMN ) today announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV)....

Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications

PRINCETON, N.J., Oct. 6 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announces that Richard E.T. Smith, Ph.D., is joining the Company as Vice President of Investor Relations and Corporate Communications. Dr. Smith will be responsible for all investor relations functions and will...

Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile

-- Study concludes there was no evidence of the development of viral resistance to R7128 after 2 weeks of monotherapy in hepatitis C patients -- PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Pharmasset (Nasdaq: VRUS) and Roche will present the R7128 monotherapy resistance profile at the ...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

...cending Dose Study Overview In June 2009, pharmasset initiated a phase 1 multiple ascending dose study ...d pan genotype activity in vitro . About pharmasset pharmasset is a clinical-stage pharmaceutical company committ...

Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences

...nvestor.pharmasset.com/events.cfm . About pharmasset pharmasset is a clinical-stage pharmaceutical company committ... of Roche. Forward-Looking Statements pharmasset "Safe Harbor" Statement under the Private Securiti...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

...l/ -- Roche, InterMune, Inc. (Nasdaq: ITMN ) and pharmasset (Nasdaq: VRUS ) today announced the first result... companies. The collaborations with InterMune and pharmasset position Roche as a leader in developing innovativ... Dial-In and Webcast Details InterMune and pharmasset will host a live webcast of a discussion of the IN...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

...tient follow-up continued for 30 days following the completion of study treatment. INFORM-1 Program In November 2008, Roche, InterMune and pharmasset initiated the first all-oral combination study of direct-acting antivirals (DAAs) in the absence of interferon or ribavirin, known as the INFORM-1 stu...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

...ent of chronic hepatitis B (HBV) infection. pharmasset recently became aware of a number of spontaneous S...ed more serious myopathy than have patients in the pharmasset clinical trials. Given the number and severity of cases observed in South Korea, pharmasset concluded it was in the best interest of patients ...

Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)

...g polymerase inhibitor of hepatitis C virus (HCV). pharmasset filed an Investigational New Drug Application (IND...eneration nucleotide analog that was discovered by pharmasset scientists" stated Dr. Michelle Berrey, Pharmasset... all of the most common HCV genotypes. About pharmasset ...

Pharmasset in Biological Technology

InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25

-- Conference Call and Webcast Scheduled -- BRISBANE, Calif., April 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that InterMune and Pharmasset, Inc. will host a live webcast of a discussion of the INFORM-1 results from the EASL conference on Saturday, April 2...

Pharmasset to Present at Canaccord Adams Conference

...stor.pharmasset.com/events.cfm . About pharmasset pharmasset is a clinical-stage pharmaceutical company committ...613-4181 Forward-Looking Statements pharmasset "Safe Harbor" Statement under the Private Securiti...

Pharmasset Reports Fiscal Second Quarter 2009 Financial Results

...$9.4 million for the quarter ended March 31, 2008. pharmasset held $79.3 million in cash and cash equivalents at...PSI-7851, and the purine series of compounds. pharmasset reported a net loss of $15.5 million, or $0.59 per..., a protease inhibitor; On April 24, 2009, pharmasset announced that its development partner, Roche, had...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

...eafter reported results from our Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF). In April, we reported with Roche and pharmasset exciting new data from INFORM-1, the first-ever combination of a nucleoside polymerase inhibitor and protease inhibitor in the absence of interferon i...

Pharmasset Reports Fiscal First Quarter 2009 Financial Results

...1 million for the quarter ended December 31, 2007. pharmasset held $51.8 million in cash and cash equivalents an...d generation HCV product candidate, PSI-7851. pharmasset reported a net loss attributable to common stockho...a protease inhibitor; -- On January 11, 2009, pharmasset announced that the company and its development par...

Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock

... The shares described above are being offered by pharmasset pursuant to a registration statement previously fi... 4, 2009, subject to customary closing conditions. pharmasset intends to use the net proceeds from the sale of t...ll free, at 1-800-808-7525, Ext. 4556. About pharmasset ...

Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients

...al activity of the combination. About pharmasset pharmasset is a clinical-stage pharmaceutical company committ...(HCV) and human immunodeficiency virus (HIV). pharmasset is currently developing three product candidates. ...

Pharmasset to Present at Two Upcoming Investor Conferences

....pharmasset.com/events.cfm . About Pharmasset pharmasset is a clinical-stage pharmaceutical company committ...us (HCV) and human immunodeficiency virus (HIV). pharmasset is currently developing three product candidates. ...e: +1 (609) 613-4181 Forward-Looking Statements pharmasset "Safe Harbor" Statement under the Private Securiti...

Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th

...company on Monday, October 13, 2008, at 11:30 AM (ET). About Pharmasset pharmasset is a clinical-stage pharmaceutical company committed to discovering, develo...us (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). pharmasset is currently developing three product candidates. Clevudine, for the treatm...

Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th

...bsite at http://investor.pharmasset.com/events.cfm . About Pharmasset pharmasset is a clinical-stage pharmaceutical company committed to discovering, develo...us (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). pharmasset is currently developing three product candidates. Clevudine, for the treatm...